Genetron Health to Participate in the 8th BioCentury-BayHelix China Healthcare Summit
Genetron Holdings Limited (Nasdaq: GTH), a leading precision oncology platform in China, will participate in the 8th BioCentury-BayHelix China Healthcare Summit from November 16-19, 2021. CFO Evan Xu will discuss capital markets in China and the U.S. during a panel, focusing on regulatory risks and investor expectations. Genetron Health specializes in molecular profiling tests and cancer management, offering comprehensive services from early screening to continuous monitoring. For more information, visit Genetron Health's website.
- None.
- None.
BEIJING, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its upcoming participation in the 8th BioCentury-BayHelix China Healthcare Summit to be held November 16-19, 2021.
Genetron Health Chief Financial Officer, Evan Xu, will be a panelist in the “Hands-On Bootcamp: Assessing the Capital Markets Situation in China and the U.S.” discussion available on-demand for conference participants. This workshop will address key C-Suite questions and discuss strategies to reduce regulatory risk while meeting investor expectations for global competitiveness.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis, and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit https://ir.genetronhealth.com/.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Investor Relations Contact
US:
Hoki Luk
Head of Investor Relations
Email: hluk@genetronhealth.us
Phone: +1 (408) 891-9255
Philip Trip Taylor
Vice President | Gilmartin Group
Email: ir@genetronhealth.com
FAQ
What event will Genetron Holdings Limited (GTH) participate in during November 2021?
Who from Genetron Holdings Limited (GTH) will be speaking at the conference?
What topics will be discussed during the panel featuring Genetron Holdings Limited (GTH)?
What does Genetron Holdings Limited (GTH) specialize in?
Where can I find more information about Genetron Holdings Limited (GTH)?
